27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Several studies with animal research associate air pollution in Alzheimer's disease (AD) neuropathology, but the actual impact of air pollution on the risk of AD is unknown. 3 key findings →
Design: cohort study Participants: 95,690 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this cohort study, higher residential PM2.5 levels, especially from agriculture and wildfires, were associated with higher rates of incident dementia, providing further evidence supporting PM2.5 reduction as a population-based approach to promote healthy cognitive aging. 5 key findings →
Design: cohort study Participants: 27 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found no evidence that exposure to road traffic noise, either independently or in combination with traffic air pollution, was associated with risk of dementia in our study area. 5 key findings →
Design: longitudinal study Participants: 1,721 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This population-based cohort study demonstrates significant association between IBD and subsequent development of dementia. 5 key findings →
Design: cohort study Participants: 1,742 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Serum IgG levels to common periodontal microbiota are associated with risk for developing incident AD. 5 key findings →
Design: cohort study Participants: 219 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In 46 634 participants (51.7% female; mean [SD] age at death, 82.4 [9.0] years), SBPs and DBPs peaked 18 to 14 years before death and then decreased progressively. 2 key findings →
Design: retrospective cohort Participants: 634 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Epidemiological evidence reveals that patients with type 2 diabetes mellitus (T2DM) have an increased risk of neurodegenerative diseases (NDs), including dementia and Parkinson's disease (PD). 3 key findings →
Design: cohort study Participants: 4,651 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ 1-40 /Aβ 1-42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design. 2 key findings →
Design: cohort study Participants: 276 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Compared with PWOH, PWH were at 58% higher risk for dementia despite HIV treatment with ART. 2 key findings →
Design: cohort study Participants: 5,381 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Incident use of neuroleptics in Ontario nursing homes is substantial. 3 key findings →
Design: cohort study Participants: 19,780 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Adults with TSCI are at a heightened risk for ADRD. 2 key findings →
Design: cohort study Participants: 7,019 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. 1 key finding →
Design: longitudinal study Participants: 400 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Primary include several amyloid PET measurements (Centiloid, SUVr, BPND , R1 ), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD-related decline. 2 key findings →
Design: cohort study Participants: 2,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Midlife insomnia (fully adjusted hazard ratio = 1.24, 95% confidence interval = 1.02-1.50) and late-life terminal insomnia (fully adjusted odds ratio = 1.94, 95% confidence interval = 1.08-3.49) were associated with a higher dementia risk. 3 key findings →
Design: longitudinal study Participants: 1,446 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The mitochondrial cascade hypothesis of Alzheimer's disease (AD) has been portrayed through molecular, cellular, and animal studies; however large epidemiological studies are lacking. 3 key findings →
Design: cohort study Participants: 790 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In a Chinese cohort of 1,275 people spanning normal cognition to dementia, this study compared three blood markers: p-tau217 rose steadily as amyloid and tau pathology worsened and was very good at both ruling out early disease and flagging advanced tau pathology. 4 key findings →
Design: cohort Participants: 1,275 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This observational study analyzed electronic health records of about 1.09 million US patients with type 2 diabetes and found that those prescribed semaglutide (a GLP-1 diabetes/weight-loss drug) were substantially less likely to receive a first-time Alzheimer's diagnosis over 3 years than those on other diabetes medications. 3 key findings →
Design: cohort Participants: 1,090,000 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
This long-running Massachusetts study tracked dementia rates over more than 30 years and found that a given person's chance of developing dementia at a given age has been steadily falling since the late 1970s. The decline was seen mainly in people with at least a high school education. 4 key findings →
Design: cohort Participants: 5,205 Evidence: high
Full summary, score breakdown and related studies → Original source
This large study followed over 274,000 members of a single California health system for 14 years and found striking differences in dementia rates by race and ethnicity. 5 key findings →
Design: cohort Participants: 274,283 Evidence: high
Full summary, score breakdown and related studies → Original source
Tracking over 10,000 people for 27 years, this landmark study found that being obese in midlife (in your 40s) nearly doubled the risk of developing dementia decades later, and being overweight also raised the risk, independent of whether someone later developed diabetes or heart disease. 4 key findings →
Design: cohort Participants: 10,276 Evidence: high
Full summary, score breakdown and related studies → Original source
In a study of nearly 190,000 older US military veterans, those who had experienced a traumatic brain injury were about 57% more likely to develop dementia over the next 9 years than veterans without a brain injury history. 4 key findings →
Design: cohort Participants: 188,764 Evidence: high
Full summary, score breakdown and related studies → Original source
These findings provide evidence for a relationship between all types of alcohol use and increased dementia risk. 5 key findings →
Design: cohort Participants: 559,559 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings add to growing evidence that women have a differential tau response to Aβ that may emerge at the point of p-tau secretion. 5 key findings →
Design: cohort Participants: 1,292 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At baseline, 2,279 dementia-free participants with available blood samples were included (median age 72 (interquartile range, 61-81) years; 62% female). 4 key findings →
Design: cohort Participants: 2,279 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In Alzheimer's disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. 3 key findings →
Design: cohort Participants: 609 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →